中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2012年
1期
44-46
,共3页
杜利清%白剑强%刘强%王彦%赵鹏%陈凤华%王宏%樊飞跃
杜利清%白劍彊%劉彊%王彥%趙鵬%陳鳳華%王宏%樊飛躍
두리청%백검강%류강%왕언%조붕%진봉화%왕굉%번비약
RAD51%氨甲蝶呤%辐射增敏
RAD51%氨甲蝶呤%輻射增敏
RAD51%안갑접령%복사증민
RAD51%Methotrexate%Radiosensitization
目的 探讨同源重组修复蛋白RAD51与氨甲蝶呤辐射增敏作用的相关性.方法 分别采用Western blot和RT-PCR法,观察γ射线、氨甲蝶呤及二者联合应用对人骨肉瘤细胞RAD51表达的影响,克隆形成实验观察氨甲蝶呤对RAD51高表达前后骨肉瘤细胞辐射增敏作用的影响.结果 氨甲蝶呤在蛋白质和RNA水平抑制RAD51的表达,氨甲蝶呤和射线联合应用可明显降低RAD51的表达水平;HOS细胞和RAD51高表达的HOS-RAD51细胞加药前后的辐射增敏比分别为1.51和0.99,表明氨甲蝶呤对HOS细胞具有较好的放射增敏性.结论 RAD51可能参与了氨甲蝶呤的辐射增敏作用.
目的 探討同源重組脩複蛋白RAD51與氨甲蝶呤輻射增敏作用的相關性.方法 分彆採用Western blot和RT-PCR法,觀察γ射線、氨甲蝶呤及二者聯閤應用對人骨肉瘤細胞RAD51錶達的影響,剋隆形成實驗觀察氨甲蝶呤對RAD51高錶達前後骨肉瘤細胞輻射增敏作用的影響.結果 氨甲蝶呤在蛋白質和RNA水平抑製RAD51的錶達,氨甲蝶呤和射線聯閤應用可明顯降低RAD51的錶達水平;HOS細胞和RAD51高錶達的HOS-RAD51細胞加藥前後的輻射增敏比分彆為1.51和0.99,錶明氨甲蝶呤對HOS細胞具有較好的放射增敏性.結論 RAD51可能參與瞭氨甲蝶呤的輻射增敏作用.
목적 탐토동원중조수복단백RAD51여안갑접령복사증민작용적상관성.방법 분별채용Western blot화RT-PCR법,관찰γ사선、안갑접령급이자연합응용대인골육류세포RAD51표체적영향,극륭형성실험관찰안갑접령대RAD51고표체전후골육류세포복사증민작용적영향.결과 안갑접령재단백질화RNA수평억제RAD51적표체,안갑접령화사선연합응용가명현강저RAD51적표체수평;HOS세포화RAD51고표체적HOS-RAD51세포가약전후적복사증민비분별위1.51화0.99,표명안갑접령대HOS세포구유교호적방사증민성.결론 RAD51가능삼여료안갑접령적복사증민작용.
Objective To evaluate the correlation between homologous recombination repair protein RAD51 and methotrexate-enhanced radiosensitivity.Methods Western blot and RT-PCR assays were used to detect RAD51 expression in HOS osteosarcoma cells exposed to γ-ray irradiation alone and in combination with methotrexate.Colony formation assay was used to test the survival fraction of HOS cells exposed to γ-rays and methotrexate.Results Methotrexate inhibited both protein and RNA expressions of RAD51,and the combination of radiation and methotrexate enhanced the inhibition of RAD51 expression.Moreover,transfection of cells with RAD51 gene decreased cellular sensitivity to methotrexate and γ-rays.The sensitizer enhancerment ratios after irradiation in combination with methotrexate were 1.51 and 0.99,respectively.Methotrenate was a preferred radiosensitizer to HOS cell.Conclusions RAD51 might be involved in the methotrexate-enhanced radiosensitivity.